Genmab's 15min chart sees Bollinger Bands narrowing, KDJ death cross confirmed.

Genmab's 15-minute chart has recently exhibited Bollinger Bands Narrowing, as well as a KDJ Death Cross at 10/06/2025 09:45. This suggests that the magnitude of fluctuations in the stock price is decreasing, and the momentum of the stock price is shifting towards the downside, with a potential for further decreases.

Genmab A/S (NASDAQ: GMAB) has been in the spotlight recently with its acquisition of Merus N.V. for approximately $8 billion. This all-cash transaction, announced on September 29, 2025, is set to be completed as early as the first quarter of 2026. The acquisition will grant Genmab full rights to petosemtamab, an EGFR × LGR5 bispecific antibody currently in two Phase 3 trials for head and neck cancer Genmab stock price target raised to $40 from $36 at H.C. Wainwright^[2].

The acquisition is expected to bolster Genmab’s portfolio significantly. Petosemtamab, in combination with Keytruda, demonstrated a 63% overall response rate in first-line PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) patients, outperforming Keytruda monotherapy’s 19% response rate Genmab stock price target raised to $40 from $36 at H.C. Wainwright^[2]. Genmab projects that petosemtamab could generate at least $1 billion in annual sales by 2029, with multi-billion-dollar annual peak revenue potential thereafter Genmab stock price target raised to $40 from $36 at H.C. Wainwright^[2].

Analysts have responded positively to the acquisition. Truist Securities raised its price target on Genmab to $49.00 from $46.00, maintaining a Buy rating Truist Securities raises Genmab stock price target to $49 on Merus acquisition^[3]. H.C. Wainwright raised its price target to $40.00 from $36.00, also maintaining a Buy rating Genmab stock price target raised to $40 from $36 at H.C. Wainwright^[2]. TD Cowen increased its price target to $32.00 from $24.00, retaining a Hold rating Genmab stock price target raised to $40 from $36 at H.C. Wainwright^[2]. Leerink Partners raised its price target to $34.00 from $32.00, keeping an Outperform rating Genmab stock price target raised to $40 from $36 at H.C. Wainwright^[2].

Despite the positive analyst sentiment, Genmab's stock has exhibited technical indicators that may warrant caution. The 15-minute chart of Genmab's stock has recently shown Bollinger Bands Narrowing, suggesting a decrease in the magnitude of price fluctuations. Additionally, a KDJ Death Cross occurred on October 6, 2025, at 09:45, indicating a potential shift in momentum towards the downside Genmab AS (GMAB) Stock Price, Trades & News | GuruFocus^[1]. These technical indicators suggest that the stock price may experience further decreases in the near future.

Genmab has also made significant strides in its clinical portfolio. The company received FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in advanced endometrial cancer, and EPKINLY® (epcoritamab) was approved by the Japan Ministry of Health, Labour and Welfare for additional indications Genmab AS (GMAB) Stock Price, Trades & News | GuruFocus^[1]. These developments highlight Genmab’s commitment to advancing its oncology pipeline.

In conclusion, while Genmab’s acquisition of Merus is a strategic move that could significantly enhance its portfolio and future prospects, investors should be mindful of the current technical indicators that suggest potential downward pressure on the stock price. As always, investors should conduct thorough due diligence and consider both fundamental and technical factors before making investment decisions.